Northwestern University Feinberg School of Medicine, Chicago, Illinois, and San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego.
Lady Davis Institute for Medical Research, Jewish General Hospital, and McGill University, Montreal, Quebec, Canada, and Radboud University, Nijmegen, The Netherlands.
Arthritis Care Res (Hoboken). 2018 Nov;70(11):1646-1652. doi: 10.1002/acr.23532.
Fear of negative evaluation is a common concern among individuals with visible differences but has received limited attention in systemic sclerosis (SSc), which can involve substantial changes to appearance. The Brief Fear of Negative Evaluation Scale (BFNE) was specifically designed to evaluate fear of negative evaluation. There are currently 3 versions of the BFNE with strong demonstrated measurement properties: two 8-item versions (BFNE-S, BFNE-8) and one 12-item version (BFNE-II). The present study evaluated these versions in SSc, and identified the most appropriate version for use among SSc patients.
Participants were 1,010 patients with SSc enrolled in the Scleroderma Patient-Centered Intervention Network cohort. Multiple group confirmatory factor analysis, Cronbach's alpha, and Pearson's product-moment correlations were used to evaluate structural validity, internal consistency reliability, and convergent and divergent validity, respectively.
Confirmatory factor analysis demonstrated that 1-factor models fit acceptably well for the 12-item BFNE-II, the 8-item BFNE-S, and the 8-item BFNE-8. Additionally, all Cronbach's alphas demonstrated excellent internal consistency reliability (BFNE-II = 0.98, BFNE-S = 0.97, BFNE-8 = 0.96), and all versions had comparable associations with measures of social anxiety, body-related attitudes, depression, age, and education.
Psychometric support was found for all 3 versions of the BFNE, although the longer 12-item BFNE-II did not improve measurement compared to the shorter 8-item versions (BFNE-S and BFNE-8). Of these 2, the BFNE-S has been more widely studied, with strong validity data in a greater number of populations. Therefore, the BFNE-S is recommended to assess fear of negative evaluation among patients with SSc.
负面评价恐惧是有可见差异的个体常见的担忧，但在系统性硬化症（SSc）中受到的关注有限，因为它会导致外貌发生重大变化。《Brief Fear of Negative Evaluation Scale（BFNE）》是专门用于评估对负面评价的恐惧的量表。目前有 3 个版本的 BFNE，具有很强的证明其测量特性：两个 8 项版本（BFNE-S、BFNE-8）和一个 12 项版本（BFNE-II）。本研究评估了 SSc 中这些版本的表现，并确定了最适合 SSc 患者使用的版本。
参与者为参加 Scleroderma Patient-Centered Intervention Network 队列的 1010 名 SSc 患者。使用多组验证性因子分析、克朗巴赫 α 系数和皮尔逊积矩相关系数分别评估结构有效性、内部一致性可靠性以及收敛和发散效度。
验证性因子分析表明，1 因素模型对 12 项 BFNE-II、8 项 BFNE-S 和 8 项 BFNE-8 的拟合都较好。此外，所有克朗巴赫 α 系数均表现出极好的内部一致性可靠性（BFNE-II=0.98，BFNE-S=0.97，BFNE-8=0.96），并且所有版本与社交焦虑、身体相关态度、抑郁、年龄和教育的测量结果都具有相似的相关性。
发现所有 3 个版本的 BFNE 都具有心理计量学支持，尽管较长的 12 项 BFNE-II 与较短的 8 项版本（BFNE-S 和 BFNE-8）相比并没有提高测量效果。在这两个版本中，BFNE-S 研究得更多，在更多人群中具有强有力的有效性数据。因此，建议在评估 SSc 患者的负面评价恐惧时使用 BFNE-S。
